Raymond James Financial Inc. Decreases Stake in LivaNova PLC $LIVN

Key Points

• Raymond James Financial Inc. has decreased its stake in LivaNova PLC by 7.3%, now holding 193,068 shares valued at approximately $7.58 million.
• Several institutional investors have increased their holdings in LivaNova, with GAMMA Investing LLC growing its stake by a remarkable 2,299.7% in the first quarter.
• LivaNova recently reported earnings of $1.05 EPS, surpassing analyst expectations and reflecting a 10.6% year-over-year revenue growth.

Raymond James Financial Inc. lowered its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 7.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 193,068 shares of the company's stock after selling 15,208 shares during the quarter. Raymond James Financial Inc. owned about 0.35% of LivaNova worth $7,584,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of LivaNova by 2,299.7% during the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after purchasing an additional 8,394 shares during the period. Two Sigma Advisers LP grew its holdings in shares of LivaNova by 148.5% during the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock worth $9,936,000 after purchasing an additional 128,200 shares during the period. CWM LLC grew its holdings in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after purchasing an additional 299 shares during the period. New York State Common Retirement Fund grew its holdings in shares of LivaNova by 28.6% during the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock worth $1,897,000 after purchasing an additional 10,733 shares during the period. Finally, Deutsche Bank AG grew its holdings in shares of LivaNova by 49.7% during the 4th quarter. Deutsche Bank AG now owns 48,905 shares of the company's stock worth $2,265,000 after purchasing an additional 16,227 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday, May 20th. Barclays boosted their price target on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, Needham & Company LLC reissued a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $59.71.

LivaNova Stock Performance

LivaNova stock opened at $56.37 on Tuesday. The stock's 50 day moving average price is $47.75 and its 200 day moving average price is $43.35. LivaNova PLC has a one year low of $32.48 and a one year high of $57.35. The firm has a market capitalization of $3.08 billion, a PE ratio of -14.49 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. During the same period in the prior year, the company posted $0.93 EPS. LivaNova's quarterly revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.